References
- 1. TUMGOR G. Cirrhosis and hepatopulmonary syndrome. World J Gastroenterol. 2014; 20(10):2586-94.
- 2. RAEVENS S., GEERTS A., STEENKISTE CV., VERHELST X., VLIERBERGHE HV., COLLE I. Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment. Liver Int. 2015:1478-3223.
- 3. FRITZ JS., FALLON MB., KAWUT SM. Pulmonary vascular complications of liver disease. Am J RespirCrit Care Med. 2013; 187:133-43.
- 4. FALLON MB., ZHAN GJ. The lung in liver disease: old problem, new concepts. Trans Am Clin Climatol Assoc. 2013; 124: 250-62.
- 5. SHAH R., MOUS AO., JOHN S. Hepatopulmonary syndrome: a rare diagnosis or missed entity. Q J Med. 2014; 107:565-66.
- 6. GRACE JA., ANGUS PW. Hepatopulmonary syndrome: update on recent advances in pathophysiology, investigation, and treatment. J Gastroenterol Hepatol. 2013; 28:213-9
- 7. KIM BJ., LEE SC., PARK SW., CHOI MS., KOH KC., PAIK SW., et al. Characteristics and prevalence of intrapulmonary shunt detected by contrast echocardiography with harmonic imaging in liver transplant candidates. Am J Cardiol. 2004; 94:525-8.
- 8. ZHANG J., FALLON MB. Hepatopulmonary syndrome: update on pathogenesis and clinical features. Nat Rev Gastroenterol Hepatol. 2012; 9(9):539-49.
- 9. FENG G., RONG H. The role of hemodynamic and vasoactive substances on hepatopulmonary syndrome. 2014; 18:380-86.
- 10. KOCH DG., BOGATKEVICH G., RAMSHESH V., LEMASTERS JJ., UFLACKER R., REUBEN A. Elevated levels of endothelin-1 in hepatic venous blood are associated with intrapulmonary vasodilatation in humans. Dig Dis Sci 2012; 57:516-23.
- 11. THENAPPAN T., GOEL A., MARSBOOM G., FANG YH., TOTH PT., ZHANG HJ., et al. A central role for CD68(+) macrophages in hepatopulmonary syndrome reversal by macrophage depletion. Am J Respir Crit Care Med. 2011; 183:1080-91.
- 12. ROBERTS KE., KAWUTS M., KROWKA MJ., BROWN RS., TROTTER JF., SHAH V., et al. Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Gastroenterology. 2010; 139:130-9.
- 13. MELO-SILVA CA., GAIOE., TREVIZOLI JE., SOUZA CS., GONCALVES AS., SOUSA GC., et al. Respiratory mechanics and lung tissue remodeling in a hepatopulmonary syndrome rat model. Respir Physiol Neurobiol. 2011; 179:326-33.
- 14. NACIF LS., ANDRAUS W., PINHEIRO RS., DUCATTI L., HADDAD LBP., D’ ALBUQUERQUE LC. The hepatopulmonary syndrome. Arq Bras Cir Dig. 2014; 27(2):145-7.
- 15. MACHICAO VI., FALLON MB. Hepatopulmonary syndrome. Semin Respir Crit Care Med. 2012; 33(1):11-6.
- 16. SILVERIO AO., GUIMARAES DC., ELIAS LFQ., MILANEZ EO., NAVES S. Are the spider angiomas skin markers of hepatopulmonary syndrome? Arq Gastroenterol. 2013;50(3):175-178.
- 17. LV Y., FAN D. Hepatopulmonary syndrome. Dig Dis Sci. 2015 Jul; 60(7):1914-23.
- 18. KHABBAZA JE., KRASUSKI RA., TONELLI AR. Intrapulmonary shunt confirmed by intracardiac echocardiography in the diagnosis of hepatopulmonary syndrome. Hepatology. 2013 October; 58(4):1514-15.
- 19. KROWKA MJ. Hepatopulmonary syndrome: monitoring at your fingertip. Dig Dis Sci. 2011Jun; 56(6):1599-600.
- 20. SUCEVEANU AI., MAZILU L., TOMESCO D., CIUFU N., PAREPA IR., SUCEVEANU AP. Screening of hepatopulmonary syndrome (HPS) with CEUS and pulse-oximetry in liver cirrhosis patients eligible for liver transplant. Chirurgia. 2013; 108(5): 684-688.
- 21. SILVA HM., REIAS G., GUEDES M., CLETO E., VIZCAINO JR., GENNERY AR., et al. A case of hepatopulmonary syndrome solved by mycophenolate mofetil (an inhibitor of angiogenesis and nitric oxide production). J Hepatol. 2013; 58:630-33.
- 22. ESRAGHIAN A., KAMYAB AA., KEW-YOON S. Pharmacological treatment for hepatopulmonary syndrome. Biomed Res Int. 2013.
- 23. WALLACE MC., JAMES AL., MARSHALL M., KONTORINIS N. Resolution of severe hepatopulmonary syndrome following transjugular portosystemic shunt procedure. BMJ Case Reports. 2012.
- 24. ENACHE I., OSWALD-MAMMOSSER M., WOEHL-JAEGLE ML., HABERSETZER F., DI MARCO P., CHARLOUX A., et al. Cirrhotic cardiomyopathy and hepatopulmonary syndrome: prevalence and prognosis in a series of patients. Respir Med. 2013; 107:1030-36.
- 25. GUPTA S., CASTEL H., RAO RV., PICARD M., LILLY L., FAUGHNAN ME., et al. Improved survival after liver transplantation in patients with hepatopulmonary syndrome. Am J Transplant. 2010; 10:354-63.
- 26. PASCASIO JM., GRILO I., LOPEZ-PARDO FJ., ORTEGA-RUIZ., TIRADO JL., SOUSA JM. Prevalence and severity of hepatopulmonary syndrome and its influence on survival in cirrhotic patients evaluated for liver transplantation. Am J Tranpl. 2014; 14: 1391-99.
- 27. YUICHI C., EGAWA H., TSUBOI T., OGA T. HONDA T., YAMAMOTO K., et al. Immediate noninvasive ventilation may improve mortality in patients with hepatopulmonary syndrome after liver transplantation. Liver Transpl. 2011; 17:144-48.
- 28. MONSEL A., MAL H., BRISSON H., LUO R., EYRAUD D., VEZINET C., et al. Extracorporeal membrane oxygenation as a bridge to liver transplantation for acute respiratory distress syndrome-induced life threatening hypoxemia aggravated by hepatopulmonary syndrome. Crit Car. 2011; 15: R234.
- 29. AUZINGER G., WILLARS C., LOVERIDGE R., BEST T., VERCUEIL A., PRACHALIAS A., et al. Extracorporeal membrane oxygenation for refractory hypoxemia after liver transplantation in severe hepatopulmonary syndrome: a solution with pitfalls. Liver Transpl. 2014; 20:1141-1144.
- 30. GOLDBERG DS., KROK K., BATRA S., TROTTER JF., KAWUT SM., FALLON MB. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of UNOS database. Gastroenterology. 2014 May; 146(5) 1256-65.
- 31. AGUILAR MP., GALLEGOS-OROZCO JF. Hepatopulmonary syndrome: is it time to redefine the MELD exception score for better organ allocation and outcomes? Ann Hepatol. 2014; 13(4):468-70.
- 32. NAYYAR D., MAN HSJ., GRANTON J., GUPTA S. Defining and characterizing severe hypoxemia after liver transplantation in hepatopulmonary syndrome. Liver Transpl. 2014; 20(2): 182-90